Denosumab marca la sexta aprobación de biosimilar de Accord en Europa. El CHMP ha emitido una opinión positiva para Denosumab, que se comercializará como Osvyrti® y Jubereq®. Osvyrti® es el segundo biosimilar de Accord para la osteoporosis, tras Sondelbay®. La aprobación del CHMP allana…
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.